Developments in contraception

Bibliography

• Chabbert-Buffet N, Gerris J, Jamin C, et al. Toward a new concept of "natural balance" in oral estroprogestin contraception. Gynecol Endocrinol 2013;29:891-6
   PubMed Web of Science ®Google Scholar
• Benagiano G, Bastianelli C, Farris M. Hormonal contraception: state of the art and future perspectives. Minerva Ginecol 2007;9:241-70
   Google Scholar
• Cheng L, Che Y, Gülmezoglu AM. Interventions for emergency contraception. Cochrane Database Syst Rev 2012;8:CD001324
   PubMed Web of Science ®Google Scholar
• Sitruk-Ware R, Nath A. Metabolic effects of contraceptive steroids. Rev Endocr Metab Disord 2011;12:63-75
   PubMed Web of Science ®Google Scholar
• Fruzzetti F, Trémollieres F, Bitzer J. An overview of the development of combined oral contraceptives containing estradiol: focus on estradiol valerate/dienogest. Gynecol Endocrinol 2012;28:400-8
   PubMed Web of Science ®Google Scholar
• Oelkers W, Foidart JM, Dombrovicz N, et al. Effects of a new oral contraceptive containing an antimineralocorticoid progestogen, drospirenone, on the renin-aldosterone system, body weight, blood pressure, glucose tolerance, and lipid metabolism. J Clin Endocrinol Metab 1995;80:1816-21
   PubMed Web of Science ®Google Scholar
• Ruana X, Seegerb H, Mueck AO. The pharmacology of dienogest. Maturitas 2012;71:337-44
   PubMed Web of Science ®Google Scholar
• Ruana X, Seegerb H, Mueck AO. The pharmacology of nomegestrol acetate. Maturitas 2012;71:345-53
   PubMed Web of Science ®Google Scholar
• Rosenberg MJ, Waugh MS, Burnhill MS. Compliance, counselling and satisfaction with oral contraceptives: a prospective evaluation. Fam Plann Perspect 1998;30:89-92
   PubMedGoogle Scholar
• Burkman RT. The transdermal contraceptive system. Am J Obstet Gynecol 2004;190:S49-53
   PubMed Web of Science ®Google Scholar
• Zieman M, Guillebaud J, Weisberg E, et al. Contraceptive efficacy and cycle control with the Ortho Evra/Evra transdermal system: the analysis of pooled data. Fertil Steril 2002;77:S13-18
   PubMed Web of Science ®Google Scholar
• Zacur HA, Hedon B, Mansour D, et al. Integrated summary of Ortho Evra/Evra contraceptive patch adhesion in varied climates and conditions. Fertil Steril 2002;77:S32-5
   PubMed Web of Science ®Google Scholar
• Audet MC, Moreau M, Koltun WD, et al. Evaluation of contraceptive efficacy and cycle control of a transdermal contraceptive patch vs an oral contraceptive: a randomized controlled trial. JAMA 2001;285:2347-54
   PubMed Web of Science ®Google Scholar
• Archer DF, Stanczyk FZ, Rubin A, Foegh M. Pharmacokinetics and adhesion of the Agile transdermal contraceptive patch (AG200-15) during daily exposure to external conditions of heat, humidity and exercise. Contraception 2013;87:212-19
   PubMed Web of Science ®Google Scholar
• Roumen FJ, Mishell DR Jr. The contraceptive vaginal ring, NuvaRing(®), a decade after its introduction. Eur J Contracept Reprod Health Care 2012;17:415-27
   PubMed Web of Science ®Google Scholar
• Vree M. Lower hormone dosage with improved cycle control. Eur J Contracept Reprod Health Care 2002;7:25-30
   Web of Science ®Google Scholar
• Brache V, Faundes A. Contraceptive vaginal rings: a review. Contraception 2010;82:418-27
   PubMed Web of Science ®Google Scholar
• Department of Reproductive Health, World Health Organization. Medical eligibility criteria for contraceptive use. 4th edition. Available from: http://www.who.int/reproductivehealth/publications/family_planning/9789241563888/en/
   Google Scholar
• Croxatto HB, Mäkäräinen L. The pharmacodynamics and efficacy of Implanon. An overview of the data. Contraception 1998;58:91S-7S
   PubMed Web of Science ®Google Scholar
• Sivin I, Campodonico I, Kiriwat O, et al. The performance of levonorgestrel rod and Norplant contraceptive implants: a 5 year randomized study. Hum Reprod 1998;13:3371-8
   PubMed Web of Science ®Google Scholar
• Mascarenhas L. Insertion and removal of Implanon. Contraception 1998;58:79S-83S
   PubMed Web of Science ®Google Scholar
• Meirik O, Fraser IS, d'Arcangues C; WHO Consultation on Implantable Contraceptives for Women. Implantable contraceptives for women. Hum Reprod Update 2003;9:49-59
   PubMed Web of Science ®Google Scholar
• Mansour D, Korver T, Marintcheva-Petrova M, Fraser IS. The effects of Implanon on menstrual bleeding patterns. Eur J Contracept Reprod Health Care 2008;13-13:28
   PubMed Web of Science ®Google Scholar
• Weisberg E, Fraser I. Australian women's experience with Implanon. Aust Fam Physician 2005;34:694-6
   PubMedGoogle Scholar
• Hidalgo MM, Lisondo C, Juliato CT, et al. Ovarian cysts in users of Implanon® and Jadelle® subdermal contraceptive implants. Contraception 2006;73:532-6
   PubMed Web of Science ®Google Scholar
• Palomba S, Falbo A, Di Cello A, et al. Nexplanon: the new implant for long-term contraception. A comprehensive descriptive review. Gynecol Endocrinol 2012;28:710-21
   PubMed Web of Science ®Google Scholar
• Ortiz ME, Croxatto HB. Copper-T intrauterine device and levonorgestrel intrauterine system: biological bases of their mechanism of action. Contraception 2007;75:S16-30
   PubMed Web of Science ®Google Scholar
• Lähteenmäki P, Bardin CW, Elomaa K, et al. Selection and performance of the levonorgestrel-releasing intrauterine system. Acta Obstet Gynecol Scand Suppl 1997;164:69-74
   PubMedGoogle Scholar
• Mansour D. The benefits and risks of using a levonorgestrel-releasing intrauterine system for contraception. Contraception 2012;85:224-34
   PubMed Web of Science ®Google Scholar
• Luukkainen T, Pakarinen P, Toivonen J. Progestin-releasing intrauterine systems. Semin Reprod Med 2001;19:355-63
   PubMed Web of Science ®Google Scholar
• Kaislasuo J, Suhonen S, Gissler M, et al. Intrauterine contraception: incidence and factors associated with uterine perforation—a population-based study. Hum Reprod 2012;27:2658-63
   PubMed Web of Science ®Google Scholar
• Bednarek PH, Jensen JT. Safety, efficacy and patient acceptability of the contraceptive and non-contraceptive uses of the LNG-IUS. Int J Womens Health 2009;1:45-58
   Google Scholar
• Croxatto HB, Brache V, Pavez M, et al. Pituitary-ovarian function following the standard levonorgestrel emergency contraceptive dose or a single 0.75 mg dose given on the days preceding ovulation. Contraception 2004;70:442-50
   PubMed Web of Science ®Google Scholar
• Novikova N, Weisberg E, Stanczyk FZ, Fraser IS. Effectiveness of levonorgestrel emergency contraception given before or after ovulation–a pilot study. Contraception 2007;75:112-18
   PubMed Web of Science ®Google Scholar
• Gemzell-Danielsson K, Berger C. Emergency contraception – mechanisms of action. Contraception 2013;87:300-8
   PubMed Web of Science ®Google Scholar
• Richardson AR, Maltz FN. Ulipristal acetate: review of the efficacy and safety of a newly approved agent for emergency contraception. Clin Ther 2012;34:24-36
   PubMed Web of Science ®Google Scholar
• Brache V, Cochon L, Deniaud M, Croxatto HB. Ulipristal acetate prevents ovulation more effectively than levonorgestrel: analysis of pooled data from three randomized trials of emergency contraception regimens. Contraception 2013;88(5):611-18
   PubMed Web of Science ®Google Scholar
• Jin J, Weisberg E, Fraser IS. Comparison of three single doses of mifepristone as emergency contraception: a randomised controlled trial. Aust N Z J Obstet Gynaecol 2005;45:489-94
   PubMed Web of Science ®Google Scholar
• Cleland K, Zhu H, Goldstuck N, et al. The efficacy of intrauterine devices for emergency contraception: a systematic review of 35 years of experience. Hum Reprod 2012;27:1994-2000
   PubMed Web of Science ®Google Scholar
• Alan Guttmacher Institute. In their own right: addressing the sexual and reproductive health needs of men worldwide. Available from: http://www.guttmacher.org/pubs/itor_intl.pdf
   Google Scholar
• Barfield A, Melo J, Coutinho E, et al. Pregnancies associated with sperm concentrations below 10 million/ml in clinical studies of a potential male contraceptive method, monthly depot medroxyprogesterone acetate and testosterone esters. Contraception 1979;20:121-7
   PubMed Web of Science ®Google Scholar
• Nieschlag E. Clinical trials in male hormonal contraception. Contraception 2010;82:457-70
   PubMed Web of Science ®Google Scholar
• Wu FC, Farley TM, Peregoudov A, Waites GM. Effects of testosterone enanthate in normal men: experience from a multicenter contraceptive efficacy study. World Health Organization Task Force on Methods for the Regulation of Male Fertility. Fertil Steril 1996;65:626-36
   PubMed Web of Science ®Google Scholar
• Nieschlag E, Kumar N, Sitruk-Ware R. 7alpha-methyl-19-nortestosterone (MENT): the population council's contribution to research on male contraception and treatment of hypogonadism. Contraception 2013;87:288-95
   PubMed Web of Science ®Google Scholar
• Lidegaard Ø, Løkkegaard E, Svendsen AL, Agger C. Hormonal contraception and risk of venous thromboembolism: national follow-up study. BMJ 2009;339:b2890
   PubMed Web of Science ®Google Scholar
• van Hylckama Vlieg A, Helmerhorst FM, Vandenbroucke JP, et al. The venous thrombotic risk of oral contraceptives, effects of estrogen dose and progestagen type: results of the MEGA case-control study. BMJ 2009;339:b2921
   PubMed Web of Science ®Google Scholar
• Jick SS, Hernandez RK. Risk of non-fatal venous thromboembolism in women using oral contraceptives containing drospirenone compared with women using oral contraceptives containing levonorgestrel: case-control study using United States claims data. BMJ 2011;340:d2151
   Web of Science ®Google Scholar
• Parkin L, Sharples K, Hernandez RK, Jick SS. Risk of venous thromboembolism in users of oral contraceptives containing drospirenone or levonorgestrel: nested case-control study based on UK General Practice Research Database. BMJ 2011;340:d2139
   Web of Science ®Google Scholar
• Lidegaard Ø, Nielsen LH, Skovlund CW, et al. Risk of venous thromboembolism from use of oral contraceptives containing different progestogens and oestrogen doses: danish cohort study, 2001–9. BMJ 2011;343:d6423
   PubMed Web of Science ®Google Scholar
• Heinemann LAJ, Dinger JC. Range of published estimates of venous thromboembolism incidence in young women. Contraception 2007;75:328-36
   PubMed Web of Science ®Google Scholar
• Bitzer J, Amy JJ, Beerthuizen R, et al. Statement on combined hormonal contraceptives containing third- or fourth-generation progestogens or cyproterone acetate, and the associated risk of thromboembolism. Eur J Contracept Reprod Health Care 2013;18:143-7
   PubMed Web of Science ®Google Scholar
• Shapiro S. Combined hormonal contraceptives and the risk of venous and arterial thromboembolism and cardiovascular death: misuse of automated databases. J Fam Plann Reprod Health Care 2013;39:89-96
   PubMedGoogle Scholar
• Reid R; Society of Obstetricians and Gynaecologists of Canada. SOGC clinical practice guideline. No. 252, December 2010. Oral contraceptives and the risk of venous thromboembolism: an update. J Obstet Gynaecol Can 2010;32:1192-204
   PubMedGoogle Scholar
• Cole JA, Norman H, Doherty M, Walker AM. Venous thromboembolism, myocardial infarction, and stroke among transdermal contraceptive system users. Obstet Gynecol 2007;109:339-46. Erratum in: Obstet Gynecol 2008;111:1449
   PubMed Web of Science ®Google Scholar
• Jick SS, Kaye JA, Russmann S, Jick H. Risk of nonfatal venous thromboembolism in women using a contraceptive transdermal patch and oral contraceptives containing norgestimate and 35 microg of ethinyl estradiol. Contraception 2006;73:223-8
   PubMed Web of Science ®Google Scholar
• Lidegaard O, Nielsen LH, Skovlund CW, Løkkegaard E. Venous thrombosis in users of non-oral hormonal contraception: follow-up study, Denmark 2001-10. BMJ 2012;344:e2990
   PubMed Web of Science ®Google Scholar
• Ali MM, Cleland J, Shah I. Causes and consequences of contraceptive discontinuation: evidence from 60 demographic and health surveys. WHO; Geneva: 2012
   Google Scholar
• Secura G. Long-acting reversible contraception: a practical solution to reduce unintended pregnancy. Minerva Ginecol 2013;65:271-7
   PubMedGoogle Scholar
• Hobbs MK, Taft AJ, Amir LH, et al. Pharmacy access to the emergency contraceptive pill: a national survey of a random sample of Australian women. Contraception 2011;83:151-8
   PubMed Web of Science ®Google Scholar
• Glasier A, Baird D. The effects of self-administering emergency contraception. N Engl J Med 1998;339:1-4
   PubMed Web of Science ®Google Scholar